Resumen

GOMEZ DE RUEDA, Felix; GORDON SANTIAGO, María del Mar  y  TENA SEMPERE, María Eugenia. Carboplatino hypersensitivity reaction by protocol no reversible desensitization. Ars Pharm [online]. 2015, vol.56, n.1, pp.32-35. ISSN 2340-9894.  https://dx.doi.org/10.4321/S2340-98942015000100005.

Platinum compounds are widely used in different tumors, being carboplatin indicated in ovarian carcinoma. The main carboplatin-dose limiting toxicity is the thrombocytopenia, however, sometimes we have seen hypersensitivity reactions that, although it is not a fact too often (8-16%), can be severe. For this reason, desensitization protocols have been developed. We report the case of a patient intervened surgically from a papillary serous carcinoma of ovary (stage IIIC) and who later received adjuvant chemotherapy with carboplatin and paclitaxel. After twenty-two months of disease-free interval, she showed unresectable abdominal relapse, so it was again treated with carboplatin and paclitaxel. During the administration of the second cycle, said severe hypersensitivity reaction to carboplatin. Attempted to desensitization unsuccessfully, can not continue with this treatment scheme and forcing to start second line with trabectedin and pegylated liposomal adriamycin.

Palabras clave : Carboplatin; Hypersensitivity; Ovarian cancer.

        · resumen en Español     · texto en Español     · Español ( pdf )